Understanding Antimicrobial Resistance

Lauren Floris, PharmD; David Cluck, PharmD, BCPS, BCIDP, AAHIVP; Abby Singleton, PharmD, BCPS


US Pharmacist. 2020;45(3):HS-10--HS-16. 

In This Article


Antimicrobial-resistant bacteria are present in every country in the world, and many common infections are becoming more difficult to treat.[10] For example, urinary tract infections (UTIs) caused by resistant Escherichia coli have reduced the efficacy of fluoroquinolones globally. Gonorrhea treatment failure with third-generation cephalosporins has been reported in at least 10 countries. More than 2.8 million antibiotic-resistant infections occur each year in the U.S., leading to more than 35,000 deaths.[6] There is also a direct relationship between the prevalence of resistant pathogens and rates of sepsis-related outcomes. In a recent study that examined this correlation in hospitalized patients in the U.S. from 2011 to 2014, the highest rates of sepsis were associated with fluoroquinolone-resistant E coli, third-generation cephalosporins and carbapenem-resistant Klebsiella species, and vancomycin-resistant Enterococcus (VRE).[11]